Next |
home / stock / eols / eols message board
Subject | By | Source | When |
---|---|---|---|
Big buy in $EOLS OTM $10 May calls | boraborak38 | investorshub | 04/28/2023 5:12:15 PM |
$EOLS 4Q22 CC transcript: | DewDiligence | investorshub | 03/09/2023 9:46:54 PM |
Yeah.that was the only surprise. They have been | boraborak38 | investorshub | 03/09/2023 12:54:57 AM |
The only surprise is the refreshed $250M shelf | DewDiligence | investorshub | 03/09/2023 12:14:12 AM |
No surprises here. | boraborak38 | investorshub | 03/08/2023 10:32:20 PM |
$EOLS reports 4Q22 results: | DewDiligence | investorshub | 03/08/2023 9:16:29 PM |
Cant wait for Aeon to be done. If | boraborak38 | investorshub | 02/22/2023 11:19:26 PM |
Aeon sold 44% of its remaining $EOLS shares | DewDiligence | investorshub | 02/22/2023 9:12:46 PM |
I really think you are reaching on this | boraborak38 | investorshub | 02/19/2023 1:13:24 AM |
I dont see that as clearly. But your | boraborak38 | investorshub | 02/17/2023 3:39:59 AM |
What the CEO clearly means by the "not | DewDiligence | investorshub | 02/17/2023 1:10:00 AM |
Comments pertain to what? That they arent including | boraborak38 | investorshub | 02/17/2023 1:01:28 AM |
Maybe. Aeon Biopharma ($EOLS' former parent company) does | DewDiligence | investorshub | 02/16/2023 11:43:24 PM |
There isnt going to be a real accurate | DewDiligence | investorshub | 02/16/2023 11:41:54 PM |
Like it or not, Evolus is going to | boraborak38 | investorshub | 02/16/2023 10:32:10 PM |
LOL? You do understand that they use the | boraborak38 | investorshub | 02/16/2023 10:29:30 PM |
$EOLS 2028 forecast of $500M in sales includes | DewDiligence | investorshub | 02/14/2023 6:47:50 PM |
Court ruling in Korea against Daewoong may end $EOLS sales of Jeuveau(a/k/a BTX): | DewDiligence | investorshub | 02/10/2023 9:40:56 AM |
$EOLS' double-dose dataset cannot be trusted... | DewDiligence | investorshub | 01/30/2023 11:50:48 PM |
$EOLS CC slides for double-dose Jeuveausee comments below: | DewDiligence | investorshub | 01/30/2023 11:48:53 PM |
News, Short Squeeze, Breakout and More Instantly...
David Moatazedi, President and Chief Executive Officer of Evolus, is first medical aesthetics leader to be a speaker at WWD Beauty CEO Summit Evolus' flagship product, Jeuveau ® is the fastest growing aesthetic toxin in the U.S. for the last three years 1 Evolus...
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that its Chief Financial Officer, Sandra Beaver, has been awarded Outstanding CFO of a Public Company by the Orange County Business Journal. The awar...
Q1 2024 Net Revenue of $59.3 Million, Up 42% from Q1 2023 Non-GAAP Loss from Operations of $0.9 Million, on Track to Non-GAAP Profitability 1 in Q4 2024 and Full Year 2025 U.S. Clinical Trials Completed for Evolysse ® Lift and Smooth fillers, FDA Submission Expect...